Government to review NPS MedicineWise

US industry leaders are pushing the Trump administration to secure enhanced intellectual property protection from Canada under a revised North American Free Trade Agreement.

The merger of Arrow and Apotex will proceed after the ACCC decided it would not oppose the two generic companies coming together.

Only one week left for researchers to apply for the Medicines New Zealand 2018 Value of Medicines Award.

Medicines Australia brought together a cross-section of stakeholders yesterday for an all-day meeting to discuss the National Medicines Policy.

When it comes to advocacy, success is about getting the basics right - keep it simple and bring some energy, act with integrity, be consistent and have 'rules of engagement', engage openly and without overt self-interest on policy, treat others in a courteous and respectful manner, and be honest.

The former managing director of Lundbeck Australia has been promoted to lead the company's operation in China.

Shadow health minister Catherine King told PharmAus18 Labor wanted to work with the industry on developing the concept of a legislated Medicines Fund and challenged the government's claim it lists every medicine recommended by the PBAC.

The government is asked to "invest poorly" on a daily basis according to Department of Health deputy secretary Penny Shakespeare.

Australia is not investing enough in health and medical research and the Greens will oppose any further reductions in the R&D Tax Incentive, according to leader Senator Richard Di Natale.

A new report from the McKell Institute, sponsored by Medicines Australia, has highlighted the financial and economic impact of early retirement caused by ill-health and called for greater investment in a range of programs.

A very clear message from PBAC chair Professor Andrew Wilson at this morning's opening session of PharmAus18 in Canberra - advocacy based on a numbers game does not work and only undermines equitable access.

Biosimilars will not qualify for the TGA-PBAC parallel process despite the requests of the industry and the potential to accelerate savings.

Recently appointed Medicines Australia CEO Liz de Somer discussed what has been a 'turbulent' time for the association, her early impressions as CEO, the priorities and approach to the political environment, the Budget risks, policy leadership and even its move to a new premise.